torc-8k_20200603.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2020

 

resTORbio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38359

81-3305277

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 


 

 

500 Boylston Street, 13th Floor

Boston, MA

02116

 

 

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (857) 315-5528

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

TORC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders

resTORbio, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 3, 2020. The following is a summary of the matters voted on at that meeting.

 

 

a)

The stockholders of the Company elected Michael Grissinger and Lynne Sullivan as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2023 and until their successor have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class I directors were as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name

  

Votes
For

 

  

Votes
Withheld

 

  

Broker
Non-Votes

 

Michael Grissinger

  

 

8,705,706

 

  

 

2,013,690

 

  

 

13,190,522

 

Lynne Sullivan

 

 

8,682,579

 

 

 

2,036,817

 

 

 

13,190,522

 

 

 

b)

The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. The results of the stockholders’ vote with respect to such ratification were as follows:

 

Votes

For

 

Votes

Against

 

Abstain

 

Broker Non-Votes

23,627.797

 

183,049

 

99,072

 

0

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 5, 2020

 

resTORbio, Inc.

 

 

 

 

 

 

By:

/s/ Chen Schor

 

 

 

Chen Schor

 

 

 

President and Chief Executive Officer